Genomic Vision

Genomic Vision Assets per Share

The Total Assets per Share of Genomic Vision (GV.PA) as of Oct 23, 2026 is 0.07 EUR. In the previous year, Total Assets per Share was 0.10 EUR — a change of -26.32% (lower).

Assets per Share

0.07EUR

YoY

-26.32%

Last updated:

Total Assets per Share of Genomic Vision is 2022 0.07 EUR. Total Assets per Share of Genomic Vision was 2021 0.10 EUR. It decreases by -26.32% lower compared to the previous year.

The Genomic Vision Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2015
0.31 EUR
Jan 1, 2016
0.19 EUR
Jan 1, 2017
0.12 EUR
Jan 1, 2018
0.12 EUR
Jan 1, 2019
0.08 EUR
Jan 1, 2020
0.10 EUR
Jan 1, 2021
0.10 EUR
Jan 1, 2022
0.07 EUR
The Genomic Vision Assets per Share history
YEARAssets per ShareYoY
0.07EUR-26.32%
0.10EUR-7.28%
0.10EUR+30.36%
0.08EUR-35.65%
0.12EUR+5.15%
0.12EUR-37.37%
0.19EUR-39.75%
0.31EUR-17.02%
0.37EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomic Vision stock

Total Assets per Share of Genomic Vision is 0.07 EUR in 2022.

Total Assets per Share of Genomic Vision changed from 0.10 EUR to 0.07 EUR, representing a -26.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Genomic Vision

All Key Metrics — Genomic Vision